Skip to main content
ADAG
NASDAQ Life Sciences

CEO Peter Luo no longer attributed beneficial ownership of 11.20% stake held by family trust

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
8
Price
$3.47
Mkt Cap
$157.32M
52W Low
$1.3
52W High
$4.75
Market data snapshot near publication time

Summary

CEO Peter Luo and Xiaohong She are no longer attributed beneficial ownership of an 11.20% stake in Adagene Inc. held by a family trust, following a trustee change.


Key Events

  • CEO's Attributed Ownership Reduced

    CEO Peter Luo and Xiaohong She are no longer deemed to beneficially own the 11.20% stake (9,390,439 shares) held by the HAN 2020 Irrevocable Trust.

  • Trustee Change for Family Trust

    The change in beneficial ownership attribution stems from a December 19, 2024, trustee change for the HAN 2020 Irrevocable Trust, where North Point Trust Company became the independent trustee.

  • Significant Stake Value

    The 11.20% stake, no longer attributed to the CEO, is valued at approximately $32.6 million based on the current stock price, representing a substantial portion of the company's market capitalization.


Analysis

This Schedule 13D/A reports a significant change in the beneficial ownership attribution for CEO Peter Luo and Xiaohong She. Due to a trustee change for the HAN 2020 Irrevocable Trust on December 19, 2024, the 11.20% stake held by the trust is no longer attributed to them. While the shares remain within a family trust, this represents a material reduction in the reported direct control and influence of the CEO over a substantial portion of the company's shares.

At the time of this filing, ADAG was trading at $3.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $157.3M. The 52-week trading range was $1.30 to $4.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADAG - Latest Insights

ADAG
Jun 08, 2026, 6:23 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $3.47
Real-time Price: $3.32 info
Change: -$0.150 (-4%) info
Market Cap: $157.32M info
ADAG
Apr 17, 2026, 4:00 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.96
Real-time Price: $3.32 info
Change: -$0.640 (-16%) info
Market Cap: $157.32M info
ADAG
Apr 02, 2026, 4:25 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.99
Real-time Price: $3.32 info
Change: -$0.670 (-17%) info
Market Cap: $157.32M info
ADAG
Apr 02, 2026, 7:11 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.90
Real-time Price: $3.32 info
Change: -$0.580 (-15%) info
Market Cap: $157.32M info
ADAG
Apr 02, 2026, 7:01 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $4.43
Real-time Price: $3.32 info
Change: -$1.11 (-25%) info
Market Cap: $157.32M info
ADAG
Apr 02, 2026, 7:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.43
Real-time Price: $3.32 info
Change: -$1.11 (-25%) info
Market Cap: $157.32M info
ADAG
Apr 02, 2026, 6:59 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $4.43
Real-time Price: $3.32 info
Change: -$1.11 (-25%) info
Market Cap: $157.32M info
ADAG
Apr 01, 2026, 5:15 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $4.76
Real-time Price: $3.32 info
Change: -$1.44 (-30%) info
Market Cap: $157.32M info
ADAG
Apr 01, 2026, 5:00 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.76
Real-time Price: $3.32 info
Change: -$1.44 (-30%) info
Market Cap: $157.32M info
ADAG
Jan 23, 2026, 8:00 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $3.32 info
Change: +$1.58 (+91%) info
Market Cap: $157.32M info